People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allakos Inc. | — | Biotechnology | Series D+ | $128.1M | $4.1B | 2017 |
| Attune Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $23.3M | $793.0M | 2018 |
Adam Tomasi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adam Tomasi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John McKearn | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Peter Moldt | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Paul Walker | 1 | 4 |
| Dan Janney | 1 | 4 |
| Roderick Wong | 1 | 4 |
| Jason Bablak | 1 | 2 |
| Nenad Tomasevic | 1 | 2 |
| Alejandro Dorenbaum | 1 | 1 |
| Christopher Bebbington | 1 | 1 |
| Andrew McDonald | 1 | 1 |
| Steve James | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.